RankingsPricing
  1. US-listed companies
  2. VERTEX PHARMACEUTICALS INC

VERTEX PHARMACEUTICALS INCVRTX

Market cap
$122.5B
P/E ratio
33.8x
Back to summarized table
Income statementBalance sheetCash flow
Dec 31,
2010		Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023
Net income-75541-51-445-739-556-842632,0971,1772,7122,3423,3223,620
Stock-based compensation expense91118114127178231238291325360429441491581
Depreciation and amortization expenses303538486362616172107110126148181
Deferred income taxes--837-2850317-121-1,512167277-155-276-536
Losses (gains) on equity securities---------19831217-149-1
Decrease in fair value of contingent consideration---------413-3-57-52
Other non-cash items, net--00-7--10-63-12-17-79-14-12-8
Accounts receivable, net3171-40-53-7105337210822622327535984
Inventories-11130-716231645326413293136323
Prepaid expenses and other assets1212121699111-17-3529892326546
Accounts payable-13715-4925-2-12937-23513212149
Accrued expenses-1172944-310389246196--305543429
Other liabilities---------3842517499209
Net cash provided by operating activities-635-268-52-513-3652368451,2701,5693,2542,6444,1303,537
Net income-75541-51-445-739-556-842632,0971,1772,7122,3423,3223,620
Stock-based compensation expense91118114127178231238291325360429441491581
Depreciation and amortization expenses303538486362616172107110126148181
Deferred income taxes--837-2850317-121-1,512167277-155-276-536
Losses (gains) on equity securities---------19831217-149-1
Decrease in fair value of contingent consideration---------413-3-57-52
Other non-cash items, net--00-7--10-63-12-17-79-14-12-8
Accounts receivable, net3171-40-53-7105337210822622327535984
Inventories-11130-716231645326413293136323
Prepaid expenses and other assets1212121699111-17-3529892326546
Accounts payable-13715-4925-2-12937-23513212149
Accrued expenses-1172944-310389246196--305543429
Other liabilities---------3842517499209
Net cash provided by operating activities-635-268-52-513-3652368451,2701,5693,2542,6444,1303,537
Payment to acquire ViaCyte, net of cash acquired---------1,154--296-
Purchases of available-for-sale debt securities---------5374315286933,787
Sales and maturities of available-for-sale debt securities1,2851,0161,3682,3481,5581,067758369432476372-920839
Sale of equity securities---------95438---
Purchases of property and equipment38357151514557999675260235205200
Investment in equity securities and notes receivable-----------7748-
Net cash used in investing activities7-------438-202-1,23599-341-321-3,142
Purchases of available-for-sale debt securities---------5374315286933,787
Sales and maturities of available-for-sale debt securities1,2851,0161,3682,3481,5581,067758369432476372-920839
Purchases of property and equipment38357151514557999675260235205200
Sale of equity securities-------------95
Investment in equity securities and notes receivable-------------31
Payments related to finite-lived intangible assets-60--1080-------58
Payment to acquire ViaCyte, net of cash acquired---------1,154--296-
Net cash used in investing activities7-------438-202-1,23599-341-321-3,142
Issuances of common stock under benefit plans3312519226627518668345289343265102186135
Repurchases of common stock--------3501925391,425-428
Payments in connection with common stock withheld for employee tax obligations----------200136172226
Payments on finance leases---------3942478645
Proceeds from finance leases-----------23--
Other financing activities---19-68-60----0-2-264-
Net cash used in financing activities425------68-71127-505-1,478-68-562
Issuances of common stock under benefit plans3312519226627518668345289343265102186135
Repurchases of common stock--------3501925391,425-428
Payments in connection with common stock withheld for employee tax obligations----------200136172226
Payments on finance leases---------3942478645
Proceeds from finance leases and other financing activities-------------2
Net cash used in financing activities425------68-71127-505-1,478-68-562
Effect of changes in exchange rates on cash---------221-13-2927
Net (decrease) increase in cash, cash equivalents and restricted cash--------9914622,8688113,712-140
Cash paid for interest--------665655565243
Income Taxes Paid, Net--9312-3612251924761,0581,677
Income Taxes Paid, Net--9312-3612251924761,0581,677
Cash paid for interest--------665655565243
Net payments due to CRISPR Therapeutics related to finite-lived intangible assets-------------180